Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Genocea Biosciences (NASDAQ: GNCA) will present a corporate overview at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 10:40 A.M. ET. CEO Chip Clark will discuss the company’s work in developing next-generation neoantigen immunotherapies, focusing on their proprietary ATLAS™ platform. A live webcast of the presentation will be available on Genocea's investor relations site, with a replay accessible for 90 days.

Genocea aims to create life-changing immunotherapies for cancer by identifying and targeting tumor antigens.

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the virtual 11^th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17^th at 10:40 A.M. ET.

A live webcast of the presentation will be available in the "Events and Presentations" tab of the investor relations section of the Genocea website at https://ir.genocea.com/events-presentations. A replay of the webcast will be archived for 90 days following the presentation.

About Genocea Biosciences, Inc.
Genocea’s mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Our proprietary ATLAS™ platform can comprehensively profile each patient’s T cell responses to potential targets, or antigens, on that patient’s tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, Inhibigens™, that drive pro-tumor immune responses. We are conducting a Phase 1/2a clinical trial for GEN-011, our investigational adoptive T cell therapy comprising neoantigen-targeted peripheral cells. We continue to monitor patients in our phase 1/2a clinical trial for GEN-009, our investigational neoantigen vaccine. In addition to our two clinical programs, we are conducting research in several areas where we believe ATLAS could be a key tool in optimizing antigen selection for therapies across a number of diseases. To learn more, please visit https://www.genocea.com.

Investor Contact:
Dan Ferry
617-430-7576
daniel@lifesciadvisors.com

FAQ

What is the date of Genocea Biosciences' presentation at the SVB Leerink Global Healthcare Conference?

Genocea Biosciences will present on February 17, 2022.

What time will the Genocea presentation begin?

The presentation will begin at 10:40 A.M. ET.

Who is presenting on behalf of Genocea Biosciences?

Chip Clark, President and CEO, will present at the conference.

Where can I watch the Genocea Biosciences conference presentation?

A live webcast will be available on Genocea's investor relations website.

How long will the webcast of Genocea's presentation be available for replay?

The replay will be accessible for 90 days following the presentation.

What is the mission of Genocea Biosciences?

Genocea aims to develop life-changing immunotherapies by identifying the right tumor targets.